摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(9'-cyclopentyl-5'-methyl-6'-oxo-5',6',8',9'-tetrahydrospiro [cyclobutane-1,7'-pyrimido[4,5-b][1,4]diazepine]-2'-ylamino)-3-methoxybenzoic acid | 1137213-43-4

中文名称
——
中文别名
——
英文名称
4-(9'-cyclopentyl-5'-methyl-6'-oxo-5',6',8',9'-tetrahydrospiro [cyclobutane-1,7'-pyrimido[4,5-b][1,4]diazepine]-2'-ylamino)-3-methoxybenzoic acid
英文别名
4-(9'-cyclopentyl-5'-methyl-6'-oxo-5',6',8',9'-tetrahydrospiro[cyclobutane-1,7'-pyrimido[4,5-b][1,4]diazepine]-2'-ylamino)-3-methoxybenzoic acid;4-[(9-cyclopentyl-5-methyl-6-oxospiro[8H-pyrimido[4,5-b][1,4]diazepine-7,1'-cyclobutane]-2-yl)amino]-3-methoxybenzoic acid
4-(9'-cyclopentyl-5'-methyl-6'-oxo-5',6',8',9'-tetrahydrospiro [cyclobutane-1,7'-pyrimido[4,5-b][1,4]diazepine]-2'-ylamino)-3-methoxybenzoic acid化学式
CAS
1137213-43-4
化学式
C24H29N5O4
mdl
——
分子量
451.525
InChiKey
DPTIZESQHOZHIF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    33
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    108
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • POLO-LIKE KINASE INHIBITORS
    申请人:Cao Sheldon X.
    公开号:US20090291938A1
    公开(公告)日:2009-11-26
    Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    提供了以下公式的化合物,用于与激酶一起使用:其中变量的定义如下。还提供了包含这些化合物的制药组合物、工具包和制造物品;用于制造这些化合物的方法和中间体;以及使用这些化合物的方法。
  • PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
    申请人:Hollick Jonathan James
    公开号:US20110046093A1
    公开(公告)日:2011-02-24
    The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR 7 ; Y is O or N—(CH 2 ) n R 19 ; n is 1, 2 or 3; m is 1 or 2; R 1 and R 2 are each independently H, alkyl or cycloalkyl; R 4 and R 4′ each independently H alkyl; or R 4 and R 4′ together form a spiro cycloalkyl group; R 19 is H, alkyl, aryl or a cycloalkyl group; R 6 is OR 8 or halogen; and R 7 and R 8 are each independently H or alkyl. Further aspects relate to pharmaceutical compositions comprising said compounds and use therefore in the treatment of proliferative disorders and the like.
    本发明涉及一种化合物,其化学式为(VII)I,或其药学上可接受的盐或酯,其中:X为NR7;Y为O或N-(CH2)nR19;n为1、2或3;m为1或2;R1和R2各自独立地为H、烷基或环烷基;R4和R4′各自独立地为H烷基;或R4和R4′共同形成一个螺环烷基;R19为H、烷基、芳基或环烷基;R6为OR8或卤素;R7和R8各自独立地为H或烷基。此外,该发明还涉及包含上述化合物的制药组合物以及其在治疗增生性疾病等方面的用途。
  • Pyrimidine derivatives as protein kinase inhibitors
    申请人:Hollick Jonathan James
    公开号:US08563542B2
    公开(公告)日:2013-10-22
    The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N—(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and R2 are each independently H, alkyl or cycloalkyl; R4 and R4′ each independently H alkyl; or R4 and R4′ together form a spiro cycloalkyl group; R19 is H, alkyl, aryl or a cycloalkyl group; R6 is OR8 or halogen; and R7 and R8 are each independently H or alkyl. Further aspects relate to pharmaceutical compositions comprising said compounds and use therefore in the treatment of proliferative disorders and the like.
    本发明涉及化合物式(VII)I,或其药学上可接受的盐或酯,其中:X是NR7;Y是O或N-(CH2)nR19;n为1、2或3;m为1或2;R1和R2分别独立地是氢、烷基或环烷基;R4和R4'分别独立地是氢、烷基;或者R4和R4'共同形成一个螺环烷基;R19是氢、烷基、芳基或环烷基;R6是OR8或卤素;R7和R8分别独立地是氢或烷基。另外,本发明还涉及包括所述化合物的制药组合物,并将其用于治疗增生性疾病等。
  • US8563542B2
    申请人:——
    公开号:US8563542B2
    公开(公告)日:2013-10-22
  • US9133199B2
    申请人:——
    公开号:US9133199B2
    公开(公告)日:2015-09-15
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 5-(2-piperidin-1-yl-ethyl)-5,11-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one 4-oxo-2-pyridin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triaza-benzocycloheptene-7-carboxylic acid ethyl ester 7-chloro-5-phenyl-1-propyl-1,3-dihydro-pyrido[3,2-e][1,4]diazepin-2-one 6-methoxy-8-methyl-4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)pteridin-7(8H)-one 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-((1S,2R)-2-hydroxycyclohexyl)-3-methoxybenzamide 8-chloro-1,2,3,4-tetrahydro-pyrazino[2,1-b]quinazolin-6-one hydrochloride salt of 3-(2-chlorophenyl)-7-[(1-hydroxymethylcyclohexyl)amino]-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1 H)-one {2-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido-[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-ethyl}-carbamic acid tert-butyl ester (7R)-8-cyclohexyl-2-[(4-fluoro-1H-indazol-5-yl)amino]-5-(3-fluorophenyl)-7-methyl-7,8-dihydropteridin-6(5H)-one 7-ethoxy-8-ethyl-9-methyl-1(3),7-dihydro-[1,3]diazepino[2,1-i]purin-10-one 3-(((1H-indol-3-yl)methylene)amino)-3,4-dihydroquinazolin-2(1H)-one 3-[[(7R)-7-benzyl-2,5,8,11,14-pentazatricyclo[8.4.0.02,6]tetradeca-1(14),3,5,10,12-pentaen-8-yl]sulfonyl]benzoic acid 5-(hydroxyamino)-11H-pyrimido[4,5-b][1,5]benzodiazepine 3-ethyl-7-(3-piperidin-1-yl-propyl)-7,12-dihydro-3H-benzo[b]pyrazolo[4',3':5,6]pyrido[4,3-e][1,4]diazepin-6-one (7R)-7-benzyl-8-[2-(trifluoromethoxy)phenyl]sulfonyl-2,5,8,12,14-pentazatricyclo[8.4.0.02,6]tetradeca-1(14),3,5,10,12-pentaene 3-(9-ethylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulen-5-yl)benzoic acid-N'-acetyl hydrazide 7-chloro-2-oxo-5-phenyl-2,3-dihydro-pyrido[3,2-e][1,4]diazepine-1-carboxylic acid allylamide 6-(4-bromobenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one (+/-)-9-methylamino-4-oxo-2-pyridin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triaza-benzocycloheptene-7-carboxylic acid ethyl ester 5-benzyl-2-(1H-indol-4-yl)-6a,7,9,10-tetrahydro-[1,4]oxazino[3,4-h]pteridin-6(5H)-one 4-{[7-(cyclopropylmethoxy)-5-methyl-6-oxo-8-(3-thienyl)-5,6-dihydropyrido[3,2-d]pyrimidin-2-yl]amino}-3-methyl-N-(1-methylpiperidin-4-yl)benzamide 6-(4-chlorobenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-benzylidene-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-(4-methoxybenzylidene)-6,11-dihydro-13H-isoquinolino[3,2-b]quinazolin-13-one 6-{[(4-dimethylamino)phenyl]methylidene}-6,11-dihydro-13H-isoquino[3,2-b]quinazolin-13-one 1H-spiro[pyrimido[4,5-b]quinoline-5,5'-pyrrolo[2,3-d]pyrimidine]-2,2',4,4',6'(1'H,3H,3'H,7'H,10H)-pentaone tert-butyl 3-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido) azetidine-1-carboxylate 4-deoxy-4-amino-7,10-methano-5-deazapteroic acid (S)-N,N-dimethyl 2-[3-(9-ethylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulen-5-yl)phenyl]-1,3-oxazole-4-carboxamide diethyl (4-{[4-{[7-(hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}benzyl)phosphonate 3-[2-(3-methyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-quinazolin-4-yl]-4-(6H-thieno[2,3-b]pyrrol-4-yl)-pyrrole-2,5-dione 4-((R)-9-cyclopentyl-7-fluoro-5-methyl-6-oxo-7-vinyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-((R)-piperidin-3-yl)benzamide (S)-N,N-dimethyl 5-[3-(9-methylamino-6-oxo-2,3,3a,4-tetrahydro-1H,6H-5,8,10,10b-tetraazabenzo[e]azulenyl)phenyl]-1,3,4-oxadiazole-2-carboxamide 4-[(6-cyclopentyl-2,5-dimethyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-(1-methyl-4-piperidyl)benzamide